Clinical Efficacy of a Combination of Thymopentin and Antituberculosis Drugs in Treating Drug-Resistant Pulmonary Tuberculosis: Meta Analysis

Figures & data

Figure 1 Literature retrieval flow chart.

Table 1 Basic Situations of Included Literatures

Author	Year of Publication	Control Group Case	Combined Thymopentin Treatment Group Case	Usage of Thymopentin	Male: Female Reference Group/Reserch Group	Age Group/Research Group	Outcome Indicator
Maimati^Citation11	2017	50	50	1mg/time/d, Intramuscular injection, 15 times	31:19/32:18	41.68±4.52/41.62±4.54	③④
Chen^Citation12	2021	40	40	1mg/time/d, NA, 30 times	25:15/24:16	40.85±4.24/40.79±4.76	⑤⑥⑧⑩
Chen^Citation13	2014	50	50	1mg/time/2d, Intramuscular injection, 120 times	29:21/28:22	73.6±2.8/73.5±2.9	④⑤⑦⑨⑪
Guan^Citation14	2008	30	31	1mg/time/2d, Intramuscular injection, 90 times	19:11/19:12	49.7/48.3	③
He^Citation15	2020	42	42	80mg/time/d, NA, 16 times	27:15/29:13	41.6±4.4/42.2±4.3	③
Ji^Citation16	2015	40	40	1mg/time/d, NA, 240 times	27:13/26:14	65.12±2.53/64.13±3.42	④
Kang^Citation17	2020	41	41	1mg/time/d, NA, 90 times	23:18/21:20	38.51±9.32/39.21±8.94	①②⑪
Li^Citation18	2021	50	50	10mg/time/d, NA, NA	27:23/28:22	39.5±3.1/39.7±2.9	③
Li^Citation19	2017	35	35	1mg/time/d, NA, 180times	18:17/19:16	70.5±4.2/71.3±4.0	④⑦⑨⑪
Li^Citation20	2020	38	38	1mg/time/2d, Intramuscular injection, 120 times	23:15/24:14	53.87±2.69/53.76±2.71	⑤⑨⑪
Li^Citation21	2013	32	33	1.6mg/time, 2time/Week, NA, 6 times	20:12/18:15	40/43	③
Liu^Citation22	2014	29	29	1mg/time/d, Intramuscular injection, 180 times	18:11/19:10	43.3±11.5/42.1±10.3	①②③
Liu^Citation23	2018	69	69	NA, Intravenous injection, NA	42:27/40:29	42.3±2.6/42.5±2.7	③④
Liu^Citation24	2016	100	100	1mg/time/d, NA, 90 times	68:32/64:36	38.32±9.33/37.54±8.43	⑥⑧⑩
Mao^Citation25	2020	30	30	1mg/time/d, NA, 180 times	18:12/17:13	48.72±4.15/49.13±4.02	⑪
Ouyang^Citation26	2019	31	31	1mg/time/d, NA, 180 times	19:12/21:10	46.01±8.2/45.33±8.5	⑥
Qi^Citation27	2007	35	32	1mg/time/d, NA, 30 times	NA	NA	①④
Wang^Citation28	2021	40	40	1mg/time/d, NA, 60 times	21:19/22:18	41.28±3.89/42.16±3.27	①④⑥⑩
Yang^Citation29	2019	53	53	1mg/time/d, NA, 60 times	33:20/34:19	43.5±3.3/43.6±3.7	③④
Yu^Citation30	2020	44	44	1mg/time /d, NA, 180 times	26:18/25:19	47.22±8.01/48.13±7.89	②④
Yu^Citation31	2016	40	40	1mg/time/2d, NA, 120 time	23:17/25:15	55.16±10.36/55.03±10.22	⑤⑨⑪
Zhang^Citation32	2011	34	34	1mg/time/2d, NA, 45 times	29:5/28:6	42.5±14.2/43.0±13.6	①②③⑤⑦⑨⑪
Zou^Citation33	2017	67	89	1mg/time/d, NA, 60 times	38:29/50:39	39.54±5.13/40.52±5.34	①⑧⑩⑥

Notes: ① Sputum culture negative rate after 2–3 months of treatment. ② Sputum culture negative rate after 6–9 months of treatment. ③ Sputum culture negative rate after the whole course of treatment. ④ Focal absorption rate of PTB. ⑤ The time to cough symptom remission. ⑥ The CD3⁺ T cell level after 2–3 months of treatment. ⑦ The CD3⁺ T cell level after 6–9 months of treatment. ⑧ The CD4⁺ T cell level after 2–3 months of treatment. ⑨ The CD4⁺ T cell level after 6–9 months of treatment. ⑩ The CD8⁺ T cell level after 2–3 months of treatment. ⑪ The CD8⁺ T cell level after 6–9 months of treatment.

Figure 2 Quality evaluation of included literatures.

Figure 3 (A) Comparison forest plots of the sputum culture negative rate after 2–3 months of treatment. (B) Comparison forest plots of the sputum culture negative rate after 6–9 months of treatment. (C) Comparison forest plots of the sputum culture negative rate after the whole course of treatment.

Figure 4 (A) Comparison forest plots of the time to cough symptom remission. (B) Comparison forest plots of focal absorption rate of PTB.

Figure 5 (A) Comparison forest plots of CD3⁺ T cell level after 2–3 months of treatment. (B) Comparison forest plots of CD3⁺ T cell level after 6–9 months of treatment. (C) Comparison forest plots of CD4⁺ T cell level after 2–3 months of treatment. (D) Comparison forest plots of CD4⁺ T cell level after 6–9 months of treatment. (E) Comparison forest plots of CD8⁺ T cell level after 2–3 months of treatment. (F) Comparison forest plots of CD8⁺ T cell level after 6–9 months of treatment.

Figure 6 Funnel plots of the sputum culture negative rate after 2–3 months of treatment.

Figure 7 Funnel plots of CD4⁺ T cell level after 6–9 months of treatment.

Maimati A, Yakun K. Clinical evaluation of thymus pentapeptide combined with conventional anti-tuberculosis drugs in the treatment of drug-resistant tuberculosis. World Latest Med Inf. 2017;17(75):97.

 Google Scholar

Chen W. Effect of thymus pentapeptide in adjuvant treatment of multidrug resistant pulmonary tuberculosis and its effect on immune function. J Med Theory Pract. 2021;34(10):1679–1680.

 Google Scholar

Chen Y, Qiao XX. Adjuvant treatment of thymopentin for drug resistance senile cavitary tuberculosis. Anhui Med J. 2014;35(3):353–355.

 Google Scholar

Guan H. Effect of thymus pentapeptide on multi-drug resistant tuberculosis. J Mod Med Health. 2008;8:1171.

 Google Scholar

He MC, Wang CC. Study on the effect of thymus pentapeptide combined with conventional anti-tuberculosis drugs in the treatment of drug-resistant tuberculosis. Contemp Med Sympo. 2020;18(10):158–159.

 Google Scholar

Ji MH. Clinical observation of thymus pentapeptide in adjuvant treatment of senile cavity-resistant pulmonary tuberculosis. Chin J Mod Drug Applicat. 2015;9(022):104–105.

 Google Scholar

Kang GN, Dang P, Hou LL. Clinical effect of thymopentin combined with antituberculosis drugs on multidrug-resistance pulmonary tuberculosis patients. Clin Res Pract. 2020;5(05):39–40.

 Google Scholar

Li J. Effects of thymopentin combined with conventional anti-tuberculosis drugs in treatment of patients with multidrug-resistant tuberculosis. Med J Chin People’s Health. 2021;33(03):6–7+10.

 Google Scholar

Li G. Clinical observation of thymus pentapeptide in adjuvant treatment of senile cavity-resistant pulmonary tuberculosis. Curr Med Sci. 2017;23(06):113–114. Article in Chinese.

 Google Scholar

Li HL. Efficacy of immunopotentiator thymopentin combined with conventional antituberculosis drugs in the treatment of patients with drug-resistant tuberculosis. Guide Chin Med. 2020;18(29):71–72. Article in Chinese.

 Google Scholar

Li ZG, Du SB, Huang J, Cheng PJ, Gong HB, Yang YS. Clinical efficacy of thymopoietin combined with routine anti-tuberculosis drugs in treating drug-resistant pulmonary tuberculosis in 33 cases. Chin Pharm. 2013;22(19):95–96. Article in Chinese.

 Google Scholar

Liu M, Zhang QL, Yu H, Meng WM. Effect of thymopentin on patients with multi-drug-resistant tuberculosis. Chin J Mod Med. 2014;24(25):87–89. Article in Chinese.

 Google Scholar

Liu LT, Cao L. Efficacy of thymus pentapeptide combined with conventional anti-tuberculosis drugs in the treatment of drug-resistant tuberculosis patients. J Med Theory Pract. 2018;31(11):1612–1613. Article in Chinese.

 Google Scholar

Liu SF, Zhao L, Xue J, et al. Effect of thymopentin in the adjunctive therapy of multi-drug resistant tuberculosis and its influence on immune function. J Clin Pulm Med. 2016;21(07):1279–1282. Article in Chinese.

 Google Scholar

Mao FL, Cui YY, Zhao CY. Clinical effect of thymopentin combined with quadruple antituberculosis regimen in the treatment of drug-resistant tuberculosis. Clin Res Pract. 2020;5(27):45–47. Article in Chinese.

 Google Scholar

Ouyang B. Observation on the effect of thymopentin in the treatment of drug-resistant tuberculosis patients and its effect on immune function and serum inflammatory factors. Chin Commun Doctors. 2019;35(14):44–45. Article in Chinese.

 Google Scholar

Qi M, Meng YJ, Zang K. Thymus pentapeptide adjuvant treatment of 32 cases of multi-drug resistant tuberculosis. Chin J Pract Med. 2007;34(2):89. Article in Chinese.

 Google Scholar

Wang Z. Effect of thymus pentapeptide on sputum negative rate and focal absorption rate in patients with drug-resistant tuberculosis. Heilongjiang Med J. 2021;34(01):92–94. Article in Chinese.

 Google Scholar

Yang T. Efficacy of thymus pentapeptide combined with conventional anti-tuberculosis drugs in the treatment of drug-resistant tuberculosis patients. Mod Diagnosis Treat. 2019;30(21):3760–3761+3887. Article in Chinese.

 Google Scholar

Yu X. Efficacy evaluation of injection thymic pentapeptide combined with 3HRZE/6HRE regimen in the treatment of drug-resistant pulmonary tuberculosis. Inner Mongolia Med J. 2020;52(06):664–665. Article in Chinese.

 Google Scholar

Yu RM, Gao Y, Yan TH. Clinical efficacy of thymopoietin combined with the conventional anti tuberculosis drugs in the treatment of drug resistant tuberculosis. Chin Health Stand Manage. 2016;7(20):139–141. Article in Chinese.

 Google Scholar

Zhang XN, Wang YB, Shi YG, Han XH. Effect of thymus pentapeptide in adjuvant treatment of drug-resistant bacterial positive pulmonary tuberculosis. Chin J Postgraduat Med. 2011;01:47–49. Article in Chinese.

 Google Scholar

Zou P, Chen L, Zhu TJ, Peng SL, Pan HL, Xia M. Effect of thymopentin on adjuvant treatment of drug resistant tuberculosis patients and its effect on immune function and inflammatory factors. Chin J Difficult Complicat Cases. 2017;16(12):1217–1220. Article in Chinese.

 Google Scholar